FDA: Pradaxa bleeding no higher than warfarin

News
Article

Bleeding rates associated with new use of dabigatran (Pradaxa, Boehringer Ingelheim) do not appear to be higher than bleeding rates associated with new use of warfarin, according to an FDA safety review of post-market reports of serious bleeding events.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.